Celularity joined the Unicorn Club after raising $290M (per supplied data) and completing post-IPO capital transactions in 2025. Headquartered in Warren, New Jersey, United States, Celularity develops placenta-derived allogeneic cell therapies targeting oncology, infectious, and degenerative diseases. Lead candidates include placental NK and stromal cell programs such as CYNK001. Funding supported clinical trials, manufacturing scale-up, and translational research, enabling early human studies and the development of cell banks for scalable, allogeneic therapeutic production.
Keep reading to learn how Celularity advances next-generation cell therapy programs.
What Is Celularity and What Does It Do?
Celularity, founded in 2016, is a cell therapy developer based in Warren, New Jersey, United States.
Celularity employs 225 people and focuses on placenta-derived cell therapeutics for cancer, infectious diseases, and degenerative conditions. The company advances clinical programs, manufacturing capabilities, and translational research to deliver off-the-shelf allogeneic therapies. Celularity also develops cell banking and manufacturing platforms to ensure consistent, scalable production, partnering with biopharma companies to accelerate combination programs and commercial readiness.
How Much Funding Has Celularity Raised?
1. Post IPO Round
- Amount Raised: $2M
- Date: October 24, 2025
- Purpose: Ongoing clinical and manufacturing support
2. Post IPO Round
- Amount Raised: $2M
- Date: July 30, 2025
- Purpose: Support late-stage programs and commercialization readiness
3. Post IPO Round
- Amount Raised: $1.03M
- Date: July 22, 2025
- Purpose: Minor capital infusions for operations
Total Funding Raised: $290M Latest Funding Date: October 2025
Key Investors
- Celgene
- Details: Major biopharma with expertise in oncology and cell therapy
- Focus Areas: Oncology, cell & gene therapy, biologics
- Notable Investments / Partnerships: Multiple cell therapy collaborations and acquisitions (e.g., Juno Therapeutics via BMS)
- United Therapeutics
- Details: Public biotech focused on rare diseases and advanced therapeutics
- Focus Areas: Cell therapy, biologics, manufacturing
- Notable Investments / Partnerships: Manufacturing investments and late-stage clinical programs
Where Is Celularity’s Headquarters?
Celularity is headquartered in Warren, New Jersey, United States, near regional biopharma research and manufacturing hubs.
What’s Next for Celularity?
Celularity will advance clinical trials, scale cGMP manufacturing, and pursue partnerships to move lead programs toward registrational studies and commercialization.
Get Investor & Funding Insights with TexAu
TexAu helps sales and business teams uncover detailed fundraising information on companies like Celularity. Use the platform to research investors, track funding rounds, and gather actionable insights to strengthen prospecting and business strategy.
Sign up for Free to access detailed investor and funding data.